NUNicole J. Ullrich

Nicole J. Ullrich

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nicole J. Ullrich has a total of 313 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Child Neurology: A Case of Concurrent Neurofibromatosis Type 1 and Multiple Sclerosis by 2024 Criteria

    by Alexandra Balshi, Cesar Alves, Nicole J. Ullrich, Leslie A. Benson

    We present a female pediatric patient with known neurofibromatosis type 1 (NF1) whose surveillance imaging began showing multifocal periventricular and juxtacortical lesions with transient enhancem...

  • Workplace Lactation in Neurology

    by Deborah A. Hall, Deborah O. Setter, Nicole J. Ullrich, Lauren E. Klaffke, Nicole R. Gonzales, Susanne Muehlschlegel, Kiran Teresa Thakur, Annise Wilson, Janis M. Miyasaki, Kathleen M. Shannon, et al.

    Federal law requires workplaces to provide appropriate space, time, and, when employees are not fully relieved of their duties during breaks, compensation to support pumping at work. The aim of this study was to assess the current landscape for lactating persons in neurology and to identify opportunities for improvement within the workplace. Respondents of a 53-question survey distributed to AAN members reported varying levels of awareness regarding institutional lactation policies. Although most lactating individuals indicated that they had adequate time and space to pump, most were not compensated during their breaks. One-third of respondents stopped pumping earlier than intended, although most did not change jobs because of lactation-related challenges and continued to recommend neurology as a career to students. Ensuring designated time, appropriate space, and compensation for lactation at both the institutional and individual levels is essential to support early-career neurologists.

  • Open Access

    Contemporary Ototoxicity Among Patients With High-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL1531

    by Mallory R. Taylor, Willem H. Collier, Kristin Knight, Johnnie K. Bass, Nicole J. Ullrich, Rochelle Bagatell, Steven G. DuBois, Arlene Naranjo, Emily Greengard, Yael Mosse, et al.

    PURPOSE: Cisplatin is a component of many high-risk neuroblastoma (HRNBL) induction regimens and causes irreversible destruction of cochlear hair cells. Historical cisplatin-induced hearing loss (CIHL) rates in patients with HRNBL range from 13% to 95%, with considerable heterogeneity due to treatment, assessment timing, and audiologic grading scales. Contemporary rates of CIHL in this vulnerable population are unknown. The purpose of this study was to describe the prevalence of end-induction CIHL using international consensus grading among patients with HRNBL enrolled on the Children's Oncology Group (COG) study ANBL1531. METHODS: Enrolled patients were randomized or assigned therapy that included a total of 360 mg/m 2 of cisplatin during induction. Audiologic evaluations were completed at baseline and end of induction (EOI). A subset of trial centers submitted EOI audiograms, which were centrally graded using the International Society of Pediatric Oncology (SIOP) ototoxicity grading scale. Evaluable participants were those with interpretable audiology results for frequencies 2-8 kHz available for central review. Communication-impacting CIHL was defined as SIOP grade ≥2. RESULTS: Among evaluable patients (n = 87), 56% (49/87) had SIOP grade >2 CIHL in the better ear following induction chemotherapy and 69% (51/74 of patients with ear-specific testing) had SIOP >2 hearing loss in the worse ear. There were no statistically significant differences in CIHL across patient demographic factors. A higher rate of CIHL was observed among patients receiving concurrent ALK inhibitor therapy (11/14, 79%), but this did not reach statistical significance. CONCLUSION: In this contemporary HRNBL cohort with central audiometry using uniform SIOP ototoxicity grading, communication-impacting CIHL affected over half of patients at EOI. Otoprotection strategies are urgently needed for patients with HRNBL who receive cisplatin.

  • Open Access

    Supplementary Tables S1 and S2 from Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA

    by Isidro Cortes-Ciriano, Christopher D. Steele, Katherine Piculell, Alyaa Al-Ibraheemi, Vanessa Eulo, Marilyn M. Bui, Aikaterini Chatzipli, Brendan C. Dickson, Dana C. Borcherding, Andrew Feber, et al.

    Supplementary Table 1 includes the metadata on all subjects, including basic demographics and medical history. Supplementary Table 2 provides statistics on chrom 8 gene expression among tumors with H3K27me3 loss. Note: no changes have been made to this file since our last resubmission.

  • Open Access

    Supplementary Figures 1-15 from Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA

    by Isidro Cortes-Ciriano, Christopher D. Steele, Katherine Piculell, Alyaa Al-Ibraheemi, Vanessa Eulo, Marilyn M. Bui, Aikaterini Chatzipli, Brendan C. Dickson, Dana C. Borcherding, Andrew Feber, et al.

    Supplementary figures provide additional details on the genomic landscape of MPNST and interesting cases within the cohort.

  • Open Access

    Neurologic morbidity and functional independence in adult survivors of childhood cancer

    by Stefanie C. Vuotto, Mingjuan Wang, M. Fatih Okcu, Daniel C. Bowers, Nicole J. Ullrich, Kirsten K. Ness, Chenghong Li, Deo Kumar Srivastava, Rebecca M. Howell, Todd M. Gibson, et al.

    ObjectiveTo examine associations between neurologic late effects and attainment of independence in adult survivors of childhood cancer treated with central nervous system (CNS)-directed therapies.MethodsA total of 7881 survivors treated with cranial radiation therapy (n = 4051; CRT) and/or intrathecal methotrexate (n = 4193; IT MTX) ([CNS-treated]; median age [range] = 25.5 years [18-48]; time since diagnosis = 17.7 years [6.8-30.2]) and 8039 without CNS-directed therapy reported neurologic conditions including stroke, seizure, neurosensory deficits, focal neurologic dysfunction, and migraines/severe headaches. Functional independence was assessed using latent class analysis with multiple indicators (independent living, assistance with routine and personal care needs, ability to work/attend school, attainment of driver's license, marital/partner status). Multivariable regression models, adjusted for age, sex, race/ethnicity, and chronic health conditions, estimated odds ratios (OR) or relative risks (RR) for associations between neurologic morbidity, functional independence, and emotional distress.ResultsAmong CNS-treated survivors, three classes of independence were identified: (1) moderately independent, never married, and non-independent living (78.7%); (2) moderately independent, unable to drive (15.6%); and (3) non-independent (5.7%). In contrast to 50% of non-CNS-treated survivors and 60% of siblings, a fourth fully independent class of CNS-treated survivors was not identified. History of stroke (OR = 2.50, 95% CI: 1.70-3.68), seizure (OR = 9.70, 95% CI: 7.37-12.8), neurosensory deficits (OR = 2.67, 95% CI: 2.16-3.31), and focal neurologic dysfunction (OR = 3.05, 95% CI: 2.40-3.88) were associated with non-independence among CNS-treated survivors. Non-independence was associated with emotional distress symptoms.InterpretationCNS-treated survivors do not attain full independence comparable to non-CNS-treated survivors or siblings. Interventions to promote independence may be beneficial for survivors with treatment-related neurological sequalae.


  • Open Access

    Cerebral Vasculopathy in Children with Neurofibromatosis Type 1

    by Laura L. Lehman, Nicole J. Ullrich

    Cerebrovascular abnormalities are a severe and often underrecognized complication of childhood neurofibromatosis type 1 (NF1). There are no prospective studies of cerebral vasculopathy in NF1; thus, the estimated frequency of vasculopathy varies between studies. The data is difficult to interpret due to the retrospective data collection and variability in whether imaging is done based on screening/surveillance or due to acute neurologic symptoms. The prevalent NF1-associated cerebral vasculopathy is moyamoya syndrome (MMS). Vascular changes can present without symptoms or with acute TIA or stroke-like symptoms or a range of progressive neurologic deficits. Advanced imaging may enhance sensitivity of neuroimaging in children. Medical and/or surgical interventions may prevent short- and long-term complications. Challenges for establishment of a screening protocol for cerebral vasculopathy in children with NF1 include the relatively large number of patients with NF1, the potential need for sedation to achieve quality imaging and the broad age range at time of detection for cerebral vascular changes. The goal of this review is to present the epidemiology, clinical presentation, imaging features and medical/surgical management of cerebral arteriopathies in children with NF1.


  • Children's Oncology Group's 2023 blueprint for research: Cancer control and supportive care

    by Adam J. Esbenshade, Lillian Sung, Julienne Brackett, L. Lee Dupuis, Brian T. Fisher, Allison Grimes, Tamara P. Miller, Nicole J. Ullrich, Christopher C. Dvorak, the Cancer Control and Supportive Care Committee

    The objective of the Cancer Control and Supportive Care (CCL) Committee in the Children's Oncology Group (COG) is to reduce the overall morbidity and mortality of therapy‐related toxicities in children, adolescents, and young adults with cancer. We have targeted five major domains that cause clinically important toxicity: (i) infections and inflammation; (ii) malnutrition and metabolic dysfunction; (iii) chemotherapy‐induced nausea and vomiting; (iv) neuro‐ and oto‐toxicty; and (v) patient‐reported outcomes and health‐related quality of life. Subcommittees for each domain prioritize randomized controlled trials and biology aims to determine which strategies best mitigate the toxicities. The findings of these trials are impactful, informing clinical practice guidelines (CPGs) and directly leading to changes in the standard of care for oncology practice. With the development of new therapies, there will be new toxicities, and the COG CCL Committee is dedicated to developing interventions to minimize acute and delayed toxicities, lessen morbidity and mortality, and improve quality of life in pediatric and young adult patients with cancer.


  • Open Access

    Supplementary Tables S1 and S2 from Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA

    by Isidro Cortes-Ciriano, Christopher D. Steele, Katherine Piculell, Alyaa Al-Ibraheemi, Vanessa Eulo, Marilyn M. Bui, Aikaterini Chatzipli, Brendan C. Dickson, Dana C. Borcherding, Andrew Feber, et al.

    Supplementary Table 1 includes the metadata on all subjects, including basic demographics and medical history. Supplementary Table 2 provides statistics on chrom 8 gene expression among tumors with H3K27me3 loss. Note: no changes have been made to this file since our last resubmission.

  • Open Access

    Supplementary Tables S1 and S2 from Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA

    by Isidro Cortes-Ciriano, Christopher D. Steele, Katherine Piculell, Alyaa Al-Ibraheemi, Vanessa Eulo, Marilyn M. Bui, Aikaterini Chatzipli, Brendan C. Dickson, Dana C. Borcherding, Andrew Feber, et al.

    Supplementary Table 1 includes the metadata on all subjects, including basic demographics and medical history. Supplementary Table 2 provides statistics on chrom 8 gene expression among tumors with H3K27me3 loss. Note: no changes have been made to this file since our last resubmission.